Gilead Stakes Claim In Oncology, Swings At Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech's lead oncology agent idelalisib is in five Phase III trials in indolent non-Hodgkin’s lymphoma and in chronic lymphocytic leukemia. Management said data reported so far compare favorably with competing agents in CLL, but that Wall Street isn't recognizing the value of its oncology candidates.